Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.
Sofie Kirial MørkMohammad KadivarKalijn Fredrike BolArianna DraghiMarie Christine Wulff WestergaardSigne Koggersbøl SkadborgNana OvergaardAnders Bundgård SørensenIda Svahn RasmussenLars Vibe AndreasenChristina Westmose YdeThomas TrolleChristian GardeJens Friis-NielsenNis NørgaardDennis ChristensenJens Vindahl KringelumMarco DoniaSine Reker HadrupInge Marie SvanePublished in: Oncoimmunology (2022)
The majority of neoantigens arise from unique mutations that are not shared between individual patients, making neoantigen-directed immunotherapy a fully personalized treatment approach. Novel technical advances in next-generation sequencing of tumor samples and artificial intelligence (AI) allow fast and systematic prediction of tumor neoantigens. This study investigates feasibility, safety, immunity, and anti-tumor potential of the personalized peptide-based neoantigen vaccine, EVX-01, including the novel CD8 + T-cell inducing adjuvant, CAF®09b, in patients with metastatic melanoma (NTC03715985). The AI platform PIONEER TM was used for identification of tumor-derived neoantigens to be included in a peptide-based personalized therapeutic cancer vaccine. EVX-01 immunotherapy consisted of 6 administrations with 5-10 PIONEER TM -predicted neoantigens as synthetic peptides combined with the novel liposome-based Cationic Adjuvant Formulation 09b (CAF®09b) to strengthen T-cell responses. EVX-01 was combined with immune checkpoint inhibitors to augment the activity of EVX-01-induced immune responses. The primary endpoint was safety, exploratory endpoints included feasibility, immunologic and objective responses. This interim analysis reports the results from the first dose-level cohort of five patients. We documented a short vaccine manufacturing time of 48-55 days which enabled the initiation of EVX-01 treatment within 60 days from baseline biopsy. No severe adverse events were observed. EVX-01 elicited long-lasting EVX-01-specific T-cell responses in all patients. Competitive manufacturing time was demonstrated. EVX-01 was shown to be safe and able to elicit immune responses targeting tumor neoantigens with encouraging early indications of a clinical and meaningful antitumor efficacy, warranting further study.
Keyphrases
- artificial intelligence
- end stage renal disease
- immune response
- ejection fraction
- chronic kidney disease
- newly diagnosed
- early stage
- machine learning
- prognostic factors
- peritoneal dialysis
- emergency department
- oxidative stress
- dna methylation
- deep learning
- drug delivery
- early onset
- big data
- high throughput
- climate change
- bone marrow
- papillary thyroid
- cell therapy